Cowen & Co. analyst Doug Schenkel downgrades Zymergen (NASDAQ:ZY) from Outperform to Market Perform.
Raymond James Maintains Strong Buy on Aveanna Healthcare Hldgs, Lowers Price Target to $12
Raymond James analyst John Ransom maintains Aveanna Healthcare Hldgs (NASDAQ:AVAH) with a Strong Buy and lowers the price target from $15 to $12.